68 related articles for article (PubMed ID: 15383272)
21. Dual-specificity protein tyrosine phosphatase VHR down-regulates c-Jun N-terminal kinase (JNK).
Todd JL; Rigas JD; Rafty LA; Denu JM
Oncogene; 2002 Apr; 21(16):2573-83. PubMed ID: 11971192
[TBL] [Abstract][Full Text] [Related]
22. Up-regulation of cyclin D1 by JNK1/c-Jun is involved in tumorigenesis of human embryo lung fibroblast cells induced by a low concentration of arsenite.
Li Y; Shen L; Xu H; Pang Y; Xu Y; Ling M; Zhou J; Wang X; Liu Q
Toxicol Lett; 2011 Oct; 206(2):113-20. PubMed ID: 21726611
[TBL] [Abstract][Full Text] [Related]
23. A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun.
Morton S; Davis RJ; McLaren A; Cohen P
EMBO J; 2003 Aug; 22(15):3876-86. PubMed ID: 12881422
[TBL] [Abstract][Full Text] [Related]
24. JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases.
Hu MC; Qiu WR; Wang YP
Oncogene; 1997 Nov; 15(19):2277-87. PubMed ID: 9393873
[TBL] [Abstract][Full Text] [Related]
25. Prolactin stimulates activation of c-jun N-terminal kinase (JNK).
Schwertfeger KL; Hunter S; Heasley LE; Levresse V; Leon RP; DeGregori J; Anderson SM
Mol Endocrinol; 2000 Oct; 14(10):1592-602. PubMed ID: 11043575
[TBL] [Abstract][Full Text] [Related]
26. A novel retro-inverso peptide is a preferential JNK substrate-competitive inhibitor.
Ngoei KR; Catimel B; Milech N; Watt PM; Bogoyevitch MA
Int J Biochem Cell Biol; 2013 Aug; 45(8):1939-50. PubMed ID: 23792175
[TBL] [Abstract][Full Text] [Related]
27. JNK2: a negative regulator of cellular proliferation.
Sabapathy K; Wagner EF
Cell Cycle; 2004 Dec; 3(12):1520-3. PubMed ID: 15611655
[TBL] [Abstract][Full Text] [Related]
28. Involvement of the c-jun N-terminal kinases JNK1 and JNK2 in complement-mediated cell death.
Gancz D; Donin N; Fishelson Z
Mol Immunol; 2009 Dec; 47(2-3):310-7. PubMed ID: 19864026
[TBL] [Abstract][Full Text] [Related]
29. Licochalcone A, a natural inhibitor of c-Jun N-terminal kinase 1.
Yao K; Chen H; Lee MH; Li H; Ma W; Peng C; Song NR; Lee KW; Bode AM; Dong Z; Dong Z
Cancer Prev Res (Phila); 2014 Jan; 7(1):139-49. PubMed ID: 24253317
[TBL] [Abstract][Full Text] [Related]
30. Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase.
Fuchs SY; Dolan L; Davis RJ; Ronai Z
Oncogene; 1996 Oct; 13(7):1531-5. PubMed ID: 8875991
[TBL] [Abstract][Full Text] [Related]
31. JNK1, but not JNK2, is required for COX-2 induction by nickel compounds.
Zhang D; Li J; Wu K; Ouyang W; Ding J; Liu ZG; Costa M; Huang C
Carcinogenesis; 2007 Apr; 28(4):883-91. PubMed ID: 17065197
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a novel JNK (c-Jun N-terminal kinase) inhibitory peptide.
Ngoei KR; Catimel B; Church N; Lio DS; Dogovski C; Perugini MA; Watt PM; Cheng HC; Ng DC; Bogoyevitch MA
Biochem J; 2011 Mar; 434(3):399-413. PubMed ID: 21162712
[TBL] [Abstract][Full Text] [Related]
33. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate.
She QB; Chen N; Bode AM; Flavell RA; Dong Z
Cancer Res; 2002 Mar; 62(5):1343-8. PubMed ID: 11888903
[TBL] [Abstract][Full Text] [Related]
34. Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway.
Oleinik NV; Krupenko NI; Krupenko SA
Oncogene; 2007 Nov; 26(51):7222-30. PubMed ID: 17525747
[TBL] [Abstract][Full Text] [Related]
35. Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells.
Yu W; Liao QY; Hantash FM; Sanders BG; Kline K
Cancer Res; 2001 Sep; 61(17):6569-76. PubMed ID: 11522656
[TBL] [Abstract][Full Text] [Related]
36. Involvement of c-Jun NH2-terminal kinase-1 in heat-induced apoptotic cell death of human monoblastic leukaemia U937 cells.
Enomoto A; Suzuki N; Liu C; Kang Y; Zhu J; Serizawa S; Matsumoto Y; Morita A; Ito M; Hosoi Y
Int J Radiat Biol; 2001 Aug; 77(8):867-74. PubMed ID: 11571020
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of T lymphocyte activation by cAMP is associated with down-regulation of two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase and c-Jun N-terminal kinase.
Tamir A; Granot Y; Isakov N
J Immunol; 1996 Aug; 157(4):1514-22. PubMed ID: 8759733
[TBL] [Abstract][Full Text] [Related]
38. Early modifications in the expression of mitogen-activated protein kinase (MAPK/ERK), stress-activated kinases SAPK/JNK and p38, and their phosphorylated substrates following focal cerebral ischemia.
Ferrer I; Friguls B; Dalfó E; Planas AM
Acta Neuropathol; 2003 May; 105(5):425-37. PubMed ID: 12677442
[TBL] [Abstract][Full Text] [Related]
39. c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells.
Khatlani TS; Wislez M; Sun M; Srinivas H; Iwanaga K; Ma L; Hanna AE; Liu D; Girard L; Kim YH; Pollack JR; Minna JD; Wistuba II; Kurie JM
Oncogene; 2007 Apr; 26(18):2658-66. PubMed ID: 17057737
[TBL] [Abstract][Full Text] [Related]
40. Differential requirement for the stress-activated protein kinase/c-Jun NH(2)-terminal kinase in RNAdamage-induced apoptosis in primary and in immortalized fibroblasts.
Iordanov MS; Wong J; Newton DL; Rybak SM; Bright RK; Flavell RA; Davis RJ; Magun BE
Mol Cell Biol Res Commun; 2000 Aug; 4(2):122-8. PubMed ID: 11170843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
